Market Place
Sourcing Support
Lee`s Pharm Announces Enrollment of 498 Patients in PIII Trial of Socazolimab
17 May 2022 //
GLOBENEWSWIRE
CSIR-IICT enters licensing agreement with Lee Pharma for synthesis of 2-DG
09 Jun 2021 //
PHARMABIZ
IICT, Lee Pharma sign agreement for synthesis of 2-DG drug for COVID-19 patients
09 Jun 2021 //
INDIA TODAY
IICT, Lee Pharma sign agreement for synthesis of 2-DG drug for COVID-19 patients
09 Jun 2021 //
INDIA TODAY
Lee’s Announces it Receives Clearance to Start Phase 3 Trial
08 Mar 2021 //
GLOBENEWSWIRE
RegeneRx, Lee`s Pharm to accelerate RGN-259 development in China
27 Mar 2019 //
BIOSPECTRUMASIA
RegeneRx and Lee`s Pharm to Accelerate RGN-259 Development in China
26 Mar 2019 //
PR NEWSWIRE
Korea`s GC Pharm inks a deal with Lee`s Pharmaceutical
14 Feb 2018 //
BIOSPECTRUM
Two Indian generics makers end battle to copy drugs amid patent debate
13 Apr 2016 //
REUTERS
SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec
29 Mar 2016 //
PR NEWSWIRE
Pfizer, Inc. v. Lee (Fed. Cir. 2016)
15 Feb 2016 //
PATENT DOCS
India’s Patent Office Rejects Lee Pharma’s Compulsory License Application
20 Jan 2016 //
TWOFOUR INSIGHT
Salvat, Lee`s Pharma Ltd Announce Exclusive License,Supply Agreement for Duoxal®
11 Jan 2016 //
PR NEWS WIRE
AstraZeneca seeks hearing patent controller regarding Lee`s CL application
16 Dec 2015 //
BUSINESS STANDARD
HK-based biopharma firm Innovent,Lee`s upbeat China with biotech buys eyed
08 Dec 2015 //
FIERCE PHARMA ASIA
Lee Pharma to appear for fresh hearing on compulsory licence
18 Nov 2015 //
THE HINDU
Lee`s Pharma affiliate licenses Tragara`s TG02 oncology treatment much of Asia
17 Nov 2015 //
FIERCE PHARMA ASIA
India rejects Lee Pharma’s compulsory licence plea
18 Aug 2015 //
THE ECONOMIC TIMES
High Court rejects AstraZeneca’s diabetes drug plea
29 Jul 2015 //
THE ECONOMIC TIMES
Lee Pharma wants licence for AstraZeneca`s diabetes drug
06 Jul 2015 //
THE ECONOMIC TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.